Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-05-27

Development of novel vaccines to control infections wlth newly emerging highly pathogenic marek's disease viruses

Objective

Novel concepts to control newly emerging and highly pathogenic Marek's disease virus (vv+ MDV-1) are needed. Different antigen formulations, routes of vaccination, and biological adjuvant will be tested. DNA vaccines encoding MDV-1 antigens expressed in all stages of the virus' life cycle (lytic, latent, tumour stage) will be constructed, with an emphasis on antigens inducing a cytotoxic T cell response. The same proteins will also be expressed by recombinant Sindbis viruses. Modified live vaccines derived from a vv+ MDV-1 strain with a deletion in gB or gM shall be constructed using the bacterial artificial chromosome technique. The routes of vaccination will be
1) in-ovo vaccination and
2) vaccination of 1- day-old chickens via various routes. The cytokine profiles after MDV-1 infection will be analysed by developing new tools and test systems, and rational approaches to immune modulation using biological adjuvant will be developed and tested.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Call for proposal

Data not available

Coordinator

FRIEDRICH-LOEFLER INSTITUTE FEDERAL RESEARCH INSTITUT FOR ANIMAL HEALTH
EU contribution
No data
Address
Boddenblick 5 A
17498 INSEL RIEMS
Germany

See on map

Total cost
No data

Participants (7)